查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1372870

骨质疏鬆药物市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按药物类型、给药途径、按应用、配销通路、地区和竞争细分

Osteoporosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type, By Route of Administration, By Application, By Distribution Channel, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年全球骨质疏鬆药物市场价值为 160.9 亿美元，预计在预测期内将出现显着增长，预计到 2028 年复合年增长率 (CAGR) 为 5.73%。

骨质疏鬆症是一种以骨组织退化和骨强度下降为特征的疾病。这种情况的诊断通常涉及使用各种影像技术，包括 X 光、电脑断层扫描 (CT) 和磁振造影 (MRI)。

目前，有多种不同剂型的药物可供选择，从标准片剂到静脉注射 (IV) 输液，可缓解骨质疏鬆症的症状。这些药物有助于恢復骨吸收和形成之间的平衡，修復微小的骨缺损，降低骨折风险，并增强患者的整体肌肉力量。

市场概况
预测期 2024-2028
2022 年市场规模 160.9亿美元
2028 年市场规模 223.6亿美元
2023-2028 年复合年增长率 5.73%
成长最快的细分市场 网路药房
最大的市场 北美洲

主要市场驱动因素

骨质疏鬆症发生率增加

无可否认，骨质疏鬆症发生率的增加导致对骨质疏鬆症药物的需求显着增加。骨质疏鬆症的特征是骨骼脆弱，更容易骨折，主要影响老年人，尤其是停经后妇女。由于荷尔蒙的变化会加速骨质流失，骨质疏鬆症对女性尤其是停经后女性的影响尤其严重。随着女性人口的增长，骨质疏鬆症的盛行率也在增加，这直接刺激了对旨在控制和缓解病情的药物的需求。

不断增加的临床试验和不断增加的老年人口

骨质疏鬆症在老年人中最常见，尤其是停经后妇女。随着全球人口老化，面临骨质疏鬆症风险的人数大幅增加。随着年龄的增长，骨密度自然下降，使得骨质疏鬆症在老年人中更常见。 - 随着主要参与者继续投资增强其技术能力，研发领域存在着巨大且不断增长的市场机会。这些投资旨在推动创新进步，满足各行业不断变化的需求。此外，市场也受到骨质疏鬆症盛行率上升的影响，骨质疏鬆症是一种以骨骼衰弱为特征的疾病。这一趋势催生了对能够有效应对骨质疏鬆症挑战的创新解决方案的需求。

提高意识和诊断

医学知识和诊断技术的进步使得骨质疏鬆症的诊断更加准确和早期。人们对该疾病及其潜在后果的认识不断提高，促使人们寻求医疗干预和治疗，从而增加了对骨质疏鬆症药物的需求。

研究与开发投资不断成长

骨质疏鬆症药物研究的不断扩大，加上主要生物製药公司投资的增加、老年人口的不断增长以及创新技术先进疗法的出现，共同推动了全球骨质疏鬆症药物市场的成长。

例如，2023 年 4 月，范安德尔研究所发表了一份报告，强调了导致骨密度降低的一个重要因素。这项发现有可能开发出更有效的药物，对患有骨质疏鬆症的女性产生较少的副作用。由于骨质疏鬆症药物研究的不断增加、创新产品的监管批准不断增加、老年人口不断增长以及技术先进疗法的进步，全球骨质疏鬆症药物市场正在显着扩张。

未来几年，由于生技和製药公司加大研发投资，市场可望成长。例如，2020年10月，义大利药品监管机构批准了骨质疏鬆药物雷洛昔芬的人体临床研究。研究人员认为，这种治疗也可能对 COVID-19 患者有潜在的好处，改善他们的健康并减少传染。临床试验的积极结果可能会导致新治疗方案的开发，从而推动未来的市场扩张。此外，全球骨质疏鬆症发生率在骨密度降低的人群中不断增加，是促进市场成长的另一个重要因素。根据《加拿大骨质疏鬆症 2022》，超过 230 万加拿大人患有骨质疏鬆症，其中 50 岁及以上成年人 80% 的骨折是由骨质疏鬆症造成的。

主要市场挑战

严格的监管环境

严格的监管环境在减少骨质疏鬆症药物的需求方面发挥了作用，主要是透过影响药物的开发、行销和取得。与所有药物一样，骨质疏鬆症药物在获得批准之前必须经过严格的临床试验并满足严格的安全性和有效性标准。这些试验可能非常耗时且耗费资源，从而延迟了新药推向市场的时间。骨质疏鬆症患者可能无法及时获得创新的治疗方案，从而减少了对现有药物的需求。

满足监管要求通常会为製药公司带来大量的研发成本。这些成本可能会导致骨质疏鬆症药物的价格上涨，这可能会限制患者的负担能力并减少患者的使用机会。监管机构优先考虑病人安全是可以理解的。虽然这很重要，但严格的安全标准有时会阻碍某些药物的供应。如果一种药物显示出即使很小的不良反应风险，从而导致对具有潜在益处的药物的需求有限，情况尤其如此。

治疗费用高昂

高昂的治疗成本对骨质疏鬆症药物市场供应商的成长构成了重大挑战。骨质疏鬆症是一种以骨骼衰弱为特征的疾病，需要长期治疗以减轻疼痛并改善功能。然而，由于没有任何治疗方法可以逆转关节损伤，患者常常面临终生的治疗疾病和使用药物预防症状的费用。此外，受各种健康状况因素的影响，治疗费用因地区而异。

根据美国疾病管制与预防中心 (CDC) 的数据，骨质疏鬆症是全球第二常见的健康状况。这种广泛的流行不仅给患者而且给医疗保健系统带来了沉重的经济负担。预计与管理骨质疏鬆症相关的巨额成本将阻碍预测期内骨质疏鬆症药物市场的成长。

解决高治疗成本问题并探索创新解决方案至关重要，以使全世界患者更容易获得和负担得起骨质疏鬆症药物。透过这样做，我们可以减轻个人和医疗保健系统的经济负担，同时确保有效管理这种普遍的健康状况。

主要市场趋势

精准医疗

针对个人遗传和生活方式因素量身定制的个人化骨质疏鬆症治疗方法的开发即将到来。这种方法旨在最大限度地提高治疗效果，同时最大限度地减少副作用。个人化医疗可以实现更精确的风险评估。有骨质疏鬆症家族史或特定遗传倾向的患者可以及早发现，从而能够采取主动干预措施来预防骨质流失和骨折。个人化医疗可能涉及根据个人的遗传和代谢特征调整药物剂量。这确保患者接受适量的药物以获得治疗效果，同时最大限度地降低副作用的风险。

接受个人化治疗的患者会接受持续监测和后续照护。这种积极主动的方法使医疗保健提供者能够评估治疗效果并根据需要进行调整，确保患者的骨骼健康保持最佳状态。

新药物标靶

正在进行的研究正在发现骨质疏鬆症药物的新分子标靶。这些目标可能包括参与骨代谢的特定蛋白质或细胞途径，为创新药物开发提供机会。随着对骨代谢分子机制的深入了解，研究人员可以设计专门针对这些机制的药物。这包括开发小分子、抗体和其他与特定蛋白质或讯号路径相互作用的治疗剂。

正在进行的研究正在揭示有关骨质疏鬆症分子标靶的丰富知识。这些发现有可能彻底改变骨质疏鬆症药物的开发，带来更有效、更有针对性和个人化的治疗，从而改善骨质疏鬆症患者的骨骼健康并降低骨折风险。

细分市场洞察

管理途径见解

根据给药途径，骨质疏鬆症市场分为口服、注射和其他。口服药物以其成本效益高且安全而闻名，儘管它们可能有轻微的副作用。据报道，有罕见的严重影响，例如颌骨坏死。然而，就有效性而言，口服药物已被证明可以成功治疗骨质疏鬆症。例如，阿崙膦酸钠 (Fosamax) 已显示其能够将髋部骨折的风险降低 50%。值得注意的是，根据针对患者偏好的研究表明，患者通常更喜欢口服药物，因为它们方便且可以避免注射或输液。这种偏好凸显了口服药物在骨质疏鬆症治疗的重要性。

地诺塞麦 (Prolia) 等注射药物已成为治疗骨质疏鬆症的高效选择，具有即时的效果。这些药物虽然通常是安全的，但确实可能会产生轻微的副作用。此外，使用它们还存在罕见但严重的下颚骨坏死 (ONJ) 风险。儘管有这些考虑，授予这些注射药物的专利保护确保了排他性，让製造商设定更高的价格。为了进一步扩大市场占有率，製造商大量投资于行销工作，进而影响处方模式。有趣的是，即使有替代治疗选择，患者的品牌忠诚度仍继续推动骨质疏鬆症药物市场。

药物类型见解

从药物类型来看，2022年双磷酸盐类药物在骨质疏鬆症药物市场中将占据重要份额。这可以归因于製药业主要参与者加大了对先进新型双磷酸盐类药物的研发投入。此外，双磷酸盐是治疗骨质疏鬆症的广泛处方药物，这进一步推动了市场的成长。

另一方面，预计配体抑制剂领域在预测期内将出现最快的成长率。这主要是因为这些药物专门用于治疗骨转移，透过充当表达其受体 RANK 的肿瘤细胞的骨化学引诱剂。因此，抑制 RANKL-RANK 路径成为骨转移的理想治疗方法。对这些药物类型的详细了解和利用有助于骨质疏鬆症治疗的进步，最终改善受该疾病影响的患者的生活品质。

区域洞察

从地区来看，北美在 2018 年占据了主要份额，并且预计将继续这一趋势。这可以归因于该地区容易获得骨质疏鬆症药物，从而促进了其增长。此外，骨质疏鬆症发病率的激增进一步刺激了对这些药物的需求。

相反，预计亚太地区在预测期内将实现最快的成长。这可以归因于该地区对使用骨质疏鬆症药物的认识不断提高。此外，不断发展的生命科学产业一直是印度、中国和马来西亚等发展中经济体市场成长的关键驱动力。强劲市场的存在以及对研发活动的关注推动了这些地区骨质疏鬆症药物市场的成长。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球骨质疏鬆药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型（副甲状腺素治疗、双磷酸盐、降钙素、选择性雌激素受体调节剂和其他药物类型）
    • 依给药途径（口服、注射、其他）
    • 按应用（原发性骨质疏鬆症和继发性骨质疏鬆症）
    • 按配销通路（医院药房、零售药房、网路药房）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图

第 6 章：北美骨质疏鬆药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型
    • 依给药途径
    • 按应用
    • 按配销通路
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲骨质疏鬆药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 药品类型
    • 依给药途径
    • 按应用
    • 按配销通路
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太地区骨质疏鬆药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 药品类型
    • 依给药途径
    • 按应用
    • 按配销通路
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章：南美洲骨质疏鬆药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 药品类型
    • 依给药途径
    • 按应用
    • 按配销通路
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲骨质疏鬆药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 药品类型
    • 依给药途径
    • 按应用
    • 按配销通路
    • 按国家/地区
  • MEA：国家分析
    • 南非骨质疏鬆症药物
    • 沙乌地阿拉伯骨质疏鬆症药物
    • 阿联酋骨质疏鬆药物

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 併购
  • 产品发布

第 13 章：全球骨质疏鬆药物市场：SWOT 分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • 商业概览
  • 服务内容
  • 最近的发展
  • 主要人员
  • SWOT分析
    • Eli Lilly and Company
    • Pfizer Inc.
    • F. Hoffmann-La Roche
    • Teva Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc.
    • Novartis International AG
    • Merck & Co. Inc.
    • Amgen Inc.
    • Radius Health Inc.
    • Actavis PLC

第 16 章：策略建议

第 17 章：关于我们与免责声明

简介目录
Product Code: 5081

The Global Osteoporosis Drugs Market, valued at USD 16.09 Billion in 2022, is poised for remarkable growth in the forecast period, with an anticipated Compound Annual Growth Rate (CAGR) of 5.73% through 2028.

Osteoporosis is a disease characterized by the deterioration of bone tissues and a decrease in bone strength. The diagnosis of this condition typically involves the use of various imaging techniques, including X-rays, computed tomography (CT), and magnetic resonance imaging (MRI).

Presently, a wide array of drugs is available in various formulations, ranging from standard tablets to intravenous (IV) infusions, to alleviate the symptoms of osteoporosis. These medications serve to restore the balance between bone resorption and formation, mend microscopic bone defects, reduce the risk of fractures, and enhance overall muscle strength in patients.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 16.09 Billion
Market Size 2028USD 22.36 Billion
CAGR 2023-20285.73%
Fastest Growing SegmentOnline Pharmacy
Largest MarketNorth America

Key Market Drivers

Increasing Incidences of Osteoporosis

The increasing incidences of osteoporosis are undeniably contributing to a significant rise in the demand for osteoporosis drugs. Osteoporosis, characterized by weakened bones that are more prone to fractures, primarily affects the elderly population, especially postmenopausal women. Osteoporosis disproportionately affects women, especially postmenopausal women, due to hormonal changes that accelerate bone loss. As the female population grows, so does the prevalence of osteoporosis, which directly fuels the demand for drugs designed to manage and mitigate the condition.

Growing Clinical Trials and Rising Geriatric Population

Osteoporosis is most common in the elderly, particularly postmenopausal women. With a globally aging population, there is a substantial increase in the number of individuals at risk of developing osteoporosis. As people age, their bone density naturally decreases, making osteoporosis more prevalent among seniors. - There is a significant and growing market opportunity in the field of research and development, as key players continue to invest in enhancing their technological capabilities. These investments are aimed at driving novel advancements that can meet the evolving needs of various industries. Additionally, the market is being influenced by the rising prevalence of osteoporosis, a condition characterized by weakened bones. This trend is creating a demand for innovative solutions that can effectively address the challenges posed by osteoporosis.

For instance, according to a report by the World Health Organization in 2022, the global population of individuals aged 60 and older is projected to reach one in six by the year 2030. By this point, the number of people over the age of 60 is expected to reach a staggering 1.4 billion, marking a significant increase from the 1 billion recorded in 2020. Looking further ahead, the number of individuals aged 60 or older is projected to double by 2050, reaching a staggering 2.1 billion. Furthermore, between 2020 and 2050, the number of people aged 80 or older is expected to triple, reaching a noteworthy 426 million.

These statistics paint a vivid picture of the demographic changes that are taking place globally, underscoring the need for innovative solutions that can cater to the needs of an aging population. As a result, the market for products and services aimed at addressing the challenges associated with aging, such as osteoporosis, is poised for significant growth and presents a unique opportunity for businesses operating in this space.

Improved Awareness and Diagnosis

Advances in medical knowledge and diagnostic technologies have led to more accurate and earlier diagnoses of osteoporosis. Increased awareness of the disease and its potential consequences prompts individuals to seek medical intervention and treatment, driving up the demand for osteoporosis drugs.

The Growing Investments in Research and Development

The expanding body of research on osteoporosis medications, coupled with increased investments by major biopharmaceutical companies, the growing elderly population, and the emergence of innovative technologically advanced therapies, collectively drive the growth of the global osteoporosis drug market.

For instance, in April 2023, the Van Andel Research Institute published a report highlighting a significant factor that contributes to reduced bone density. This discovery holds the potential for developing more efficient medications with fewer adverse effects for women with osteoporosis. The global osteoporosis drugs market is witnessing significant expansion due to increasing research studies on osteoporosis drugs, rising regulatory approvals for innovative products, a growing geriatric population, and advancements in technologically advanced therapies.

In the upcoming years, the market is poised to grow as a result of increased investment in research and development by biotechnology and pharmaceutical companies. For example, in October 2020, the Italian pharmaceutical regulatory body approved human clinical studies for the osteoporosis medicine raloxifene. Researchers believe that this treatment may also have potential benefits for individuals with COVID-19, improving their well-being and reducing contagion. Positive outcomes from clinical trials could lead to the development of new therapeutic options, thereby driving future market expansion. Furthermore, the increasing incidence of osteoporosis worldwide among individuals with reduced bone density is another important factor contributing to market growth. According to Osteoporosis Canada 2022, more than 2.3 million Canadians suffer from osteoporosis, with osteoporosis being responsible for 80% of fractures in adults aged 50 and older.

Key Market Challenges

Stringent Regulatory Environment

A stringent regulatory environment has played a role in decreasing the demand for osteoporosis drugs, primarily by impacting drug development, marketing, and access. Osteoporosis drugs, like all pharmaceuticals, must undergo rigorous clinical trials and meet stringent safety and efficacy criteria before gaining approval. These trials can be time-consuming and resource-intensive, delaying the introduction of new drugs to the market. Patients suffering from osteoporosis may not have timely access to innovative treatment options, decreasing demand for existing drugs.

Meeting regulatory requirements often entails substantial research and development costs for pharmaceutical companies. These costs can translate into higher prices for osteoporosis drugs, potentially limiting affordability and reducing patient access. Regulatory agencies, understandably, prioritize patient safety. While this is essential, the stringent safety standards can sometimes hinder the availability of certain drugs. This is particularly true if a drug shows even a remote risk of adverse effects, leading to limited demand for drugs with potential benefits.

High Costs Of Treatment

The high costs of treatment pose a significant challenge for the growth of the osteoporosis drugs market vendors. Osteoporosis, a condition characterized by weakened bones, requires long-term management to reduce pain and improve functions. However, as no therapy has the potential to reverse joint damage, patients often face life-long expenses for treating the disease and preventing symptoms using drugs. Moreover, the cost of treatments varies across regions, influenced by various health condition factors.

According to the Centers for Disease Control and Prevention (CDC), osteoporosis is the second most prevalent health condition treated globally. This widespread prevalence imposes a high financial burden not only on patients but also on healthcare systems. The substantial costs associated with managing osteoporosis are expected to hinder the growth of the osteoporosis drugs market during the forecast period.

It is crucial to address the issue of high treatment costs and explore innovative solutions to make osteoporosis drugs more accessible and affordable for patients worldwide. By doing so, we can alleviate the financial burden on individuals and healthcare systems while ensuring effective management of this prevalent health condition.

Key Market Trends

Precision Medicine

The development of personalized osteoporosis treatments tailored to an individual's genetic and lifestyle factors is on the horizon. This approach aims to maximize the effectiveness of therapies while minimizing side effects. Personalized medicine allows for more precise risk assessment. Patients with a family history of osteoporosis or specific genetic predispositions can be identified early, enabling proactive interventions to prevent bone loss and fractures. Personalized medicine may involve adjusting medication dosages based on an individual's genetic and metabolic characteristics. This ensures that patients receive the right amount of medication to achieve therapeutic benefits while minimizing the risk of side effects.

Patients undergoing personalized treatment receive ongoing monitoring and follow-up care. This proactive approach allows healthcare providers to assess treatment efficacy and make adjustments as needed, ensuring that the patient's bone health remains optimized.

Novel Drug Targets

Ongoing research is uncovering new molecular targets for osteoporosis drugs. These targets may include specific proteins or cellular pathways involved in bone metabolism, offering opportunities for innovative drug development. With a deeper understanding of the molecular mechanisms underlying bone metabolism, researchers can design drugs that specifically target these mechanisms. This includes the development of small molecules, antibodies, and other therapeutic agents tailored to interact with specific proteins or signaling pathways.

Ongoing research is uncovering a wealth of knowledge about the molecular targets involved in osteoporosis. These discoveries hold the potential to revolutionize the development of osteoporosis drugs, leading to more effective, targeted, and personalized treatments that improve bone health and reduce the risk of fractures in individuals living with this condition.

Segmental Insights

Route of Administration Insights

Based on the route of administration, the market for osteoporosis is segmented into oral, injectable, and others. Oral drugs are known for being cost-effective and safe, although they may have mild side effects. Rare serious effects, such as osteonecrosis of the jaw, have been reported. However, in terms of effectiveness, oral medications have proven successful in treating osteoporosis. For instance, alendronate (Fosamax) has shown its ability to reduce the risk of hip fractures by 50%. Notably, patients commonly prefer oral drugs due to their convenience and the avoidance of injections or infusions, as indicated by studies focusing on patient preferences. This preference highlights the importance of oral medications in the management of osteoporosis.

Injectable drugs like denosumab (Prolia) have emerged as highly effective options with immediate effects for treating osteoporosis. These medications, while generally safe, do come with the potential for mild side effects. Additionally, there is a rare but serious risk of osteonecrosis of the jaw (ONJ) associated with their use. Despite these considerations, the patent protection granted to these injectable drugs ensures exclusivity, allowing manufacturers to set higher prices. To further maximize their market presence, manufacturers heavily invest in marketing efforts, which in turn influence prescribing patterns. Interestingly, brand loyalty among patients continues to drive the Osteoporosis Drugs Market, even in the presence of alternative treatment options.

Drug Type Insights

In terms of Drug Type, the bisphosphonates accounted for a significant share of the osteoporosis drugs market in 2022. This can be attributed to the increased investment in research and development of advanced novel bisphosphonates drugs by major players in the pharmaceutical industry. Moreover, bisphosphonates are widely prescribed drugs for the treatment of osteoporosis, which further drives the growth of the market.

On the other hand, the rank ligand inhibitors segment is projected to witness the fastest growth rate during the forecast period. This is primarily due to the fact that these drugs are specifically used to treat bone metastasis by acting as a chemoattractant to bone for tumor cells expressing its receptor, RANK. As a result, the inhibition of the RANKL-RANK pathway serves as an ideal treatment approach for bone metastasis. The detailed understanding and utilization of these drug types contribute to the advancement of osteoporosis treatment, ultimately improving the quality of life for patients affected by this condition.

Regional Insights

Region wise, North America accounted for the major share in 2018 and is expected to continue this trend. This can be attributed to the easy availability of osteoporosis drugs in the region, which has contributed to its growth. Additionally, the surge in the incidence of osteoporosis has further fueled the demand for these drugs.

On the contrary, Asia-Pacific is anticipated to register the fastest growth during the forecast period. This can be attributed to the increasing awareness regarding the use of osteoporosis drugs in the region. Furthermore, the constantly evolving life science industry has been a key driver of the market's growth in developing economies such as India, China, and Malaysia. The presence of a robust market and the focus on research and development activities have propelled the growth of the osteoporosis drugs market in these regions.

Key Market Players

  • Eli Lilly and Company
  • Pfizer Inc.
  • F. Hoffmann-La Roche
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc.
  • Novartis International AG
  • Merck & Co. Inc.
  • Amgen Inc.
  • Radius Health Inc.
  • Actavis PLC

Report Scope:

In this report, the Global Osteoporosis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Osteoporosis Drugs Market, By Drug Type:

  • Parathyroid Hormone Therapy
  • Bisphosphonates
  • Calcitonin
  • Selective Estrogen Receptor Modulators
  • Other Drug Types

Osteoporosis Drugs Market, By Route of Administration:

  • Oral
  • Injectables
  • Others

Osteoporosis Drugs Market, By Application:

  • Primary Osteoporosis
  • Secondary Osteoporosis

Osteoporosis Drugs Market, By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Osteoporosis Drugs Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Osteoporosis Drugs Market.

Available Customizations:

  • Global Osteoporosis Drugs market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Osteoporosis Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, Selective Estrogen Receptor Modulators, and Other Drug Types)
    • 5.2.2. By Route of Administration (Oral, Injectables, Others)
    • 5.2.3. By Application (Primary Osteoporosis and Secondary Osteoporosis)
    • 5.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 5.2.5. By Region
    • 5.2.6. By Company (2022)
  • 5.3. Market Map

6. North America Osteoporosis Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Route Of Administration
    • 6.2.3. By Application
    • 6.2.4. By Distribution Channel
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Osteoporosis Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Route Of Administration
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By Distribution Channel
    • 6.3.2. Canada Osteoporosis Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Route Of Administration
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By Distribution Channel
    • 6.3.3. Mexico Osteoporosis Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Route Of Administration
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By Distribution Channel

7. Europe Osteoporosis Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. Drug Type
    • 7.2.2. By Route Of Administration
    • 7.2.3. By Application
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Osteoporosis Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Route Of Administration
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. United Kingdom Osteoporosis Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Route Of Administration
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. Italy Osteoporosis Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Route Of Administration
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By Distribution Channel
    • 7.3.4. France Osteoporosis Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Route Of Administration
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By Distribution Channel
    • 7.3.5. Spain Osteoporosis Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Route Of Administration
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By Distribution Channel

8. Asia-Pacific Osteoporosis Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. Drug Type
    • 8.2.2. By Route Of Administration
    • 8.2.3. By Application
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Osteoporosis Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Route Of Administration
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. India Osteoporosis Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Route Of Administration
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. Japan Osteoporosis Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Route Of Administration
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. South Korea Osteoporosis Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Route Of Administration
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Australia Osteoporosis Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Route Of Administration
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By Distribution Channel

9. South America Osteoporosis Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. Drug Type
    • 9.2.2. By Route Of Administration
    • 9.2.3. By Application
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Osteoporosis Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Route Of Administration
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. Argentina Osteoporosis Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Route Of Administration
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. Colombia Osteoporosis Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Route Of Administration
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Osteoporosis Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. Drug Type
    • 10.2.2. By Route Of Administration
    • 10.2.3. By Application
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Osteoporosis Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Route Of Administration
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Saudi Arabia Osteoporosis Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Route Of Administration
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. UAE Osteoporosis Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Route Of Administration
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Osteoporosis Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Service Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. Eli Lilly and Company
    • 15.5.2. Pfizer Inc.
    • 15.5.3. F. Hoffmann-La Roche
    • 15.5.4. Teva Pharmaceutical Industries Ltd.
    • 15.5.5. GlaxoSmithKline plc.
    • 15.5.6. Novartis International AG
    • 15.5.7. Merck & Co. Inc.
    • 15.5.8. Amgen Inc.
    • 15.5.9. Radius Health Inc.
    • 15.5.10. Actavis PLC

16. Strategic Recommendations

17. About Us & Disclaimer